ZA988519B - Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C - Google Patents

Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C

Info

Publication number
ZA988519B
ZA988519B ZA988519A ZA988519A ZA988519B ZA 988519 B ZA988519 B ZA 988519B ZA 988519 A ZA988519 A ZA 988519A ZA 988519 A ZA988519 A ZA 988519A ZA 988519 B ZA988519 B ZA 988519B
Authority
ZA
South Africa
Prior art keywords
amantadine
ifn
alpha
treatment
chronic hepatitis
Prior art date
Application number
ZA988519A
Other languages
English (en)
Inventor
Friederike Zahm
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA988519B publication Critical patent/ZA988519B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA988519A 1997-09-18 1998-09-17 Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C ZA988519B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97116220 1997-09-18

Publications (1)

Publication Number Publication Date
ZA988519B true ZA988519B (en) 1999-03-18

Family

ID=8227366

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA988519A ZA988519B (en) 1997-09-18 1998-09-17 Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C

Country Status (12)

Country Link
US (1) US20030031647A1 (xx)
EP (1) EP1011714A2 (xx)
JP (1) JP2001516725A (xx)
KR (1) KR100364938B1 (xx)
CN (1) CN1276730A (xx)
AR (1) AR013498A1 (xx)
AU (1) AU746648B2 (xx)
BR (1) BR9812466A (xx)
CA (1) CA2302834A1 (xx)
TR (1) TR200000728T2 (xx)
WO (1) WO1999013894A2 (xx)
ZA (1) ZA988519B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089066A1 (en) * 2005-02-15 2006-08-24 Neuromolecular Pharmaceuticals, Inc. Combinations therapy for treatment of demyelinating conditions
US8268948B2 (en) * 2006-07-21 2012-09-18 Nektar Therapeutics Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
US8575102B2 (en) * 2008-08-01 2013-11-05 Nektar Therapeutics Conjugates having a releasable linkage

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
AU5157998A (en) * 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C

Also Published As

Publication number Publication date
AR013498A1 (es) 2000-12-27
AU746648B2 (en) 2002-05-02
EP1011714A2 (en) 2000-06-28
AU9743098A (en) 1999-04-05
TR200000728T2 (tr) 2000-09-21
BR9812466A (pt) 2000-09-19
CN1276730A (zh) 2000-12-13
CA2302834A1 (en) 1999-03-25
KR100364938B1 (ko) 2002-12-18
WO1999013894A2 (en) 1999-03-25
US20030031647A1 (en) 2003-02-13
JP2001516725A (ja) 2001-10-02
WO1999013894A3 (en) 1999-06-03
KR20010024044A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
HU228218B1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
ZA979096B (en) Viral and cancer treatment
ZA95878B (en) Therapeutic guanidines
EP0973510A4 (en) USE OF AMANTADINE FOR TREATING HEPATITIS C
PL335160A1 (en) Treatment of hiv and carcinoma
HK1020259A1 (en) Composition for use in the treatment and prevention of hyperuricemia.
DE69707471T2 (de) Metalloberflächenbehandlung
EG21712A (en) Treatment of insulin resistance
EP0971949A4 (en) COMBINATIONS AND COMPLEXES OF FETUIM WITH THERAPEUTIC AGENTS
HK1018271A1 (en) Substituted benzylamines and their use for the treatment of depression
AU2418499A (en) Org-5222 in the treatment of depression
GB2332437B (en) Metal surface treatment agent
ZA988519B (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
GB9705200D0 (en) Well treatment with particles
GB2288134B (en) Metal surface treatment agent
GB2290232B (en) Body and back support
DE9400138U1 (de) Hartgewebe-Kunststoff-Verbundkörper
GB9424415D0 (en) Treatment of painted surfaces
IL132848A0 (en) Treatment of hepatic cirrhosis
IL131409A0 (en) The proliferation of cell-inhibiting peptide and its use
GB9822885D0 (en) Use of interferon alpha for treatment of asthma
GB2277829B (en) Surface treatment of metallic components
SI1077068T1 (en) Utilization of interferon alpha 5 in the treatment of viral hepatopathies
ZA988304B (en) The treatment of liquids